BioCentury
ARTICLE | Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

January 8, 2020 1:23 AM UTC
Updated on Jan 8, 2020 at 1:26 AM UTC

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could replace the Alexion drug as standard of care for PNH.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) rose $8.54 (28%) to $38.73 Tuesday, gaining $546 million in market cap, after showing the C3 inhibitor met the primary endpoint in the Phase III PEGASUS trial to treat PNH...

BCIQ Company Profiles

Apellis Pharmaceuticals Inc.

BCIQ Target Profiles

Complement 3 (C3)